Lenograstim + chemotherapy for small cell lung cancer: cost effectiveness "finely balanced"

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1542, 2006-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lenograstim + chemo for SCLC: cost effectiveness "finely balanced"

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 505, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Increasing the Dose Intensity of Chemotherapy with Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: Based on Data from the Medical Research Council LU19 Trial

By Bojke Laura

PharmacoEconomics, Vol. 24, Iss. 5, 2006-01 ,pp. : 443-452

Adis International

Access to resources Recommend Favorite

Dose intensification in small cell lung cancer chemotherapy

By Middleton M. Thatcher N.

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 293-302

Informa Healthcare

Access to resources Recommend Favorite

Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer

Current Medicinal Chemistry, Vol. 9, Iss. 8, 2002-04 ,pp. : 893-898

Bentham Science Publishers

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer

By Holmes J.

PharmacoEconomics, Vol. 22, Iss. 9, 2004-01 ,pp. : 581-589

Adis International

Access to resources Recommend Favorite